Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by C2N Diagnostics, LLC

C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests to Help Diagnose Alzheimer’s Disease

Today 9:00 EST

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization

November 13, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test

October 01, 2025

From C2N Diagnostics, LLC

Via Business Wire

New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients

September 25, 2025

From C2N Diagnostics, LLC

Via Business Wire

Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease

September 03, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older

August 25, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Announces Major Global Expansion, Adds Six New International Partners

August 07, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias

July 15, 2025

From C2N Diagnostics, LLC

Via Business Wire

Samsung Invests in C2N Diagnostics

March 13, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom

February 24, 2025

From C2N Diagnostics, LLC

Via Business Wire

Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease

January 31, 2025

From C2N Diagnostics, LLC

Via Business Wire

First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology

January 28, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease

January 15, 2025

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease

September 30, 2024

From C2N Diagnostics, LLC

Via Business Wire

C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide

September 25, 2024

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health

August 07, 2024

From C2N Diagnostics, LLC

Via Business Wire

JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care

July 28, 2024

From C2N Diagnostics, LLC

Via Business Wire

C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories

June 27, 2024

From C2N Diagnostics, LLC

Via Business Wire

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

March 06, 2024

From C2N Diagnostics, LLC

Via Business Wire

Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease

November 16, 2023

From C2N Diagnostics, LLC

Via Business Wire

New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease

November 07, 2023

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology

October 25, 2023

From C2N Diagnostics, LLC

Via Business Wire

On World Alzheimer’s Day, C2N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach

September 21, 2023

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF

August 17, 2023

From C2N Diagnostics, LLC

Via Business Wire

Real-World Evidence Shows Healthcare Providers Use C2N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions

August 08, 2023

From C2N Diagnostics, LLC

Via Business Wire

C2N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research

March 29, 2023

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight

February 16, 2023

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood-Based Biomarkers in the Diagnosis of Alzheimer’s Disease

December 09, 2022

From C2N Diagnostics, LLC

Via Business Wire

C2N Diagnostics Introduces the PrecivityAD2™ Blood Test

November 29, 2022

From C2N Diagnostics, LLC

Via Business Wire

C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments

October 21, 2022

From C2N Diagnostics, LLC

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.